Somewhat Favorable News Coverage Somewhat Unlikely to Impact Esperion Therapeutics (ESPR) Share Price

News coverage about Esperion Therapeutics (NASDAQ:ESPR) has trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Esperion Therapeutics earned a coverage optimism score of 0.23 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.3997370810822 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of analysts have recently weighed in on ESPR shares. Northland Securities reaffirmed a “buy” rating and issued a $72.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Chardan Capital reaffirmed a “neutral” rating and issued a $75.00 price target (up from $20.00) on shares of Esperion Therapeutics in a research note on Tuesday, December 5th. Cowen started coverage on shares of Esperion Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $64.00 price target for the company. Stifel Nicolaus reaffirmed a “buy” rating and issued a $70.00 price target on shares of Esperion Therapeutics in a research note on Wednesday, October 4th. Finally, Needham & Company LLC raised shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating and upped their price target for the stock from $72.00 to $81.00 in a research note on Thursday, December 14th. Seven analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $60.85.

Esperion Therapeutics (NASDAQ ESPR) traded up $5.02 during midday trading on Tuesday, hitting $64.38. 846,539 shares of the company were exchanged, compared to its average volume of 1,003,047. Esperion Therapeutics has a twelve month low of $10.71 and a twelve month high of $65.20. The company has a market cap of $1,660.00, a P/E ratio of -9.38 and a beta of 2.73.

Esperion Therapeutics (NASDAQ:ESPR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same period last year, the company posted ($0.77) EPS. sell-side analysts predict that Esperion Therapeutics will post -7.3 earnings per share for the current fiscal year.

In related news, Director Nicole Vitullo sold 9,326 shares of the business’s stock in a transaction that occurred on Wednesday, December 6th. The shares were sold at an average price of $53.85, for a total value of $502,205.10. Following the sale, the director now directly owns 2,472 shares in the company, valued at approximately $133,117.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 32.50% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Esperion Therapeutics (ESPR) Share Price” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.com-unik.info/2017/12/26/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-esperion-therapeutics-espr-share-price.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Insider Buying and Selling by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit